Cellectis SA Cellectis (NASDAQ: CLLS) Join Hands With Cytovia To Develop Natural Killer Cells Cellectis (NASDAQ: CLLS) revealed that it has partnered with Cytovia Therapeutics Inc. Both the firm signed a planned examination as well as a cooperation agreement to create TALEN gene-edited iPSC NK and CAR-NK cells.
